Ascendis Pharma (NASDAQ: ASND) director details warrants and RSU grants
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Ascendis Pharma A/S director Cha Albert has filed an initial ownership report showing a mix of ordinary shares, warrants and restricted stock units. The filing lists 3,730 ordinary shares held directly. It also discloses fully vested warrants over 542 ordinary shares at an exercise price of $62.1700 expiring on December 11, 2028, 7,500 ordinary shares at $108.0000 expiring on December 10, 2029, 6,420 ordinary shares at $176.2800 expiring on December 10, 2030, and 3,053 ordinary shares at $139.6500 expiring on December 9, 2031. In addition, Cha holds restricted stock units covering 1,374, 2,070 and 1,930 ordinary shares, each representing a right to receive one American Depositary Share, with vesting beginning on March 1, 2027.
Positive
- None.
Negative
- None.
Insider Trade Summary
8 transactions reported
Mixed
8 txns
Insider
Cha Albert
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Warrants | -- | -- | -- |
| holding | Warrants | -- | -- | -- |
| holding | Warrants | -- | -- | -- |
| holding | Warrants | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Warrants — 542 shares (Direct);
Restricted Stock Units — 1,374 shares (Direct);
Ordinary Shares — 3,730 shares (Direct)
Footnotes (1)
- Includes American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share. The warrants are fully vested and currently exercisable. The restricted stock units vest on March 1, 2027 and have no expiration date. Each restricted stock unit represents a contingent right to receive one ADS. The restricted stock units vest in two equal annual installments beginning on March 1, 2027. The restricted stock units vest in three equal annual installments beginning on March 1, 2027.
FAQ
What does Cha Albert’s Form 3 filing for Ascendis Pharma (ASND) show?
The Form 3 shows initial ownership by director Cha Albert in Ascendis Pharma A/S, including ordinary shares, fully vested warrants, and restricted stock units, outlining current equity exposure and future share rights.
What warrants are reported in Cha Albert’s Ascendis Pharma (ASND) Form 3?
The filing lists fully vested warrants over 542, 7,500, 6,420 and 3,053 ordinary shares, with exercise prices of $62.1700, $108.0000, $176.2800 and $139.6500, expiring between 2028 and 2031.
What restricted stock units does Cha Albert hold in Ascendis Pharma?
Cha Albert holds restricted stock units over 1,374, 2,070 and 1,930 ordinary shares, each representing a right to receive one ADS. These RSUs begin vesting in installments starting on March 1, 2027.
Does the Form 3 indicate any recent buying or selling by Cha Albert in ASND?
The Form 3 presents holdings information only and does not identify any open-market purchases or sales. It establishes Cha Albert’s positions in shares, warrants, and RSUs as of the reporting date.